Tealwood Asset Management Inc. Sells 16,786 Shares of Corcept Therapeutics Incorporated $CORT

Tealwood Asset Management Inc. cut its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 53.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,370 shares of the biotechnology company’s stock after selling 16,786 shares during the period. Tealwood Asset Management Inc.’s holdings in Corcept Therapeutics were worth $500,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CORT. Royal Bank of Canada raised its position in shares of Corcept Therapeutics by 18.9% during the first quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock valued at $1,757,000 after buying an additional 2,444 shares during the last quarter. Amundi bought a new position in shares of Corcept Therapeutics during the first quarter worth $450,000. NewEdge Advisors LLC purchased a new position in Corcept Therapeutics during the first quarter valued at $518,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in Corcept Therapeutics by 8.6% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 24,231 shares of the biotechnology company’s stock valued at $1,779,000 after acquiring an additional 1,916 shares during the last quarter. Finally, Creative Planning increased its holdings in Corcept Therapeutics by 49.4% in the 2nd quarter. Creative Planning now owns 31,828 shares of the biotechnology company’s stock valued at $2,336,000 after acquiring an additional 10,520 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Director G. Leonard Baker Jr. bought 100,000 shares (~$3.3M) at about $33.14 on March 17, a meaningful insider purchase that signals management confidence and can support short‑term demand. Read More.
• Neutral Sentiment: Short‑interest reports for March 19–20 show effectively zero reported short interest (days‑to‑cover ≈ 0), which appears anomalous and likely reflects reporting quirks rather than a genuine absence of short sellers; this creates uncertainty about short‑seller pressure signals.
• Negative Sentiment: Multiple shareholder‑rights firms (Hagens Berman, Schall, DJS, Pomerantz, Rosen, Glancy, others) have issued class‑action/lead‑plaintiff notices tied to alleged FDA issues and a federal court patent loss — a concentrated legal PR wave that raises litigation risk, could increase future liabilities, and likely weighs on investor confidence. Read More. Read More.
• Negative Sentiment: Zacks Research sharply cut EPS forecasts across 2026–2027 and maintains a “Strong Sell” stance — analyst downgrades and lower near‑term earnings expectations increase downside pressure on valuation and can amplify selling if guidance or legal exposure worsens. Read More.

Corcept Therapeutics Stock Performance

Shares of NASDAQ:CORT opened at $34.64 on Friday. The company has a current ratio of 2.92, a quick ratio of 2.85 and a debt-to-equity ratio of 0.01. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $117.33. The company has a market capitalization of $3.68 billion, a price-to-earnings ratio of 42.24 and a beta of 0.29. The firm’s 50-day moving average is $37.46 and its 200 day moving average is $61.87.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. During the same period in the previous year, the business earned $0.26 EPS. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. Research analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on CORT shares. UBS Group began coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price objective for the company. Zacks Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Truist Financial set a $50.00 target price on shares of Corcept Therapeutics in a research report on Wednesday, December 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Finally, HC Wainwright reduced their price objective on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $77.17.

Insider Activity at Corcept Therapeutics

In related news, insider William Guyer sold 8,233 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $35.99, for a total transaction of $296,305.67. Following the completion of the sale, the insider directly owned 2,231 shares of the company’s stock, valued at approximately $80,293.69. This trade represents a 78.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director G Leonard Baker, Jr. acquired 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were acquired at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the acquisition, the director owned 1,146,631 shares in the company, valued at $37,999,351.34. This trade represents a 9.55% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders sold 48,233 shares of company stock worth $1,817,306. Company insiders own 20.80% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.